MUCODYNE

This brand name is authorized in Japan, Netherlands, United Kingdom, South Africa

Active ingredients

The drug MUCODYNE contains one active pharmaceutical ingredient (API):

1 Carbocisteine UNII 740J2QX53R - CARBOCYSTEINE

Carbocisteine (5-carboxymethyl L-cysteine) has been shown in normal and bronchitic animal models to affect the nature and amount of mucus glycoprotein that is secreted by the respiratory tract. An increase in the acid:neutral glycoprotein ratio of the mucus and a transformation of serous cells to mucus cells is known to be the initial response to irritation and will normally be followed by hypersecretion. Read about Carbocisteine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MUCODYNE Capsule, hard	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
MUCODYNE Syrup	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R05CB03	Carbocisteine	R Respiratory system → R05 Cough and cold preparations → R05C Expectorants, excl. combinations with cough suppressants → R05CB Mucolytics
Discover more medicines within R05CB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 162086, 175708, 33291, 337583, 373910, 381536, 97575
Country: JP	医薬品医療機器総合機構	Identifier(s): 2233002F1174, 2233002F2022, 2233002Q1035, 2233002R2029
Country: NL	Z-Index G-Standaard	Identifier(s): 14282704
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 3166
Country: ZA	Health Products Regulatory Authority	Identifier(s): 27/10.2.2/0395